Acuitas Therapeutics: Lifesaving Lipid Nanoparticle Technology

The Pfizer/BioNTech COVID-19 vaccine COMIRNATY?, administered to billions around the world to reduce the risk of serious illness or death from COVID-19, is enabled by the lipid nanoparticle (LNP) delivery technology developed by Acuitas Therapeutics , a Vancouver-based biotech company that specializes in developing LNP delivery systems for nucleic acid therapeutics – including mRNA vaccines.

The Acuitas LNP enables the mRNA vaccine to do its important – and often lifesaving – work, delivering the mRNA safely into human cells.

In the thick of the pandemic, when much of the world was hit with lockdowns, scientists at Acuitas were working flat out to support the development of the COVID-19 vaccine.

Acuitas was founded in 2009 by Drs. Thomas Madden, Michael Hope and Pieter Cullis. The founders have spent more than four decades focusing on the development of LNP technology. Dr. Madden is the President & CEO of Acuitas.

The ongoing research and development by the Acuitas team has facilitated a revolution in medicine, creating the potential to treat novel viruses such as COVID-19, but also historically challenging diseases such as malaria, HIV, tuberculosis and cancer.???

Through ongoing R&D, the safety and efficacy of Acuitas’ LNP (validated billions of times on the global stage), their commitment to supporting their team, the mentorship of young scientists, and their dedicated focus on fostering a culture of innovation in the region, Drs. Madden, Hope and Cullis have become key figures in the Metro Vancouver biotech community.

Acuitas’ contributions to research and development in the scientific field are clear, and the company’s success is now a testament to the founders’ pioneering work.